ArticleJournal of fungi (Basel, Switzerland)2021
Chronic Pulmonary Aspergillosis: Disease Severity Using Image Analysis and Correlation with Systemic Proinflammation and Predictors of Clinical Outcome.
Article in Journal of fungi (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 12 citations in OpenAlex.
- Investigating the efficacy and safety of bronchoscopic removal of aspergilloma in PTB-CCPA.Annals of medicine · 2026Article
- Is Pulmonary Mycoses Shadowed by Tuberculosis? Mandate to Hit the Bull's Eye-An Indian Perspective.Pathogens (Basel, Switzerland) · 2025Review
- Serum Type 2 Cytokine Levels Are Elevated in a Chronic Pulmonary Aspergillosis Subgroup with High Serum Total Immunoglobulin E Level.Journal of fungi (Basel, Switzerland) · 2025Article
- Immune markers for pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: a narrative review.Frontiers in immunology · 2025Review
- A combination of burn wound injury andmBio · 2023Article
- Diagnosis of Chronic Pulmonary Aspergillosis: Clinical, Radiological or Laboratory?Journal of fungi (Basel, Switzerland) · 2023Review
- Chronic pulmonary aspergillosis: comprehensive insights into epidemiology, treatment, and unresolved challenges.Therapeutic advances in infectious diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
(1) Background: The presentation of chronic pulmonary aspergillosis (CPA) ranges from single granuloma to fibrosis in the affected lung. CPA can be divided into five categories according to European Respirology Society (ERS) guidance but is usually assessed by clinical physicians. Computer-based quantitative lung parenchyma analysis in CPA and its correlation with clinical manifestations, systemic inflammation, and angiogenesis have never been investigated. (2) Method: Forty-nine patients with CPA and 36 controls were prospectively enrolled. Pulmonary function tests (forced vital capacity (FVC), forced expiratory volume in one second (FEV
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.